Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,401–5,500 of 15,747
Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients
Singer, J., Le, N., Mattes, D., Klamminger, V., Hackner, K., Kolinsky, N., Scherb, M., Errhalt, P., Kreye, G., Pecherstorfer, M., et al. (2021) · Cancers · doi:10.3390/cancers13174312 · Cited by 19
“In this trial, only a few tumor patients (3%) were included [3].”
BackgroundAckland, J., Watson, A., Wilkinson, T. M. A., & Staples, K. J. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.738987 · Cited by 18
“potentially signifies the beginning of a new era of vaccination technology, which may allow for development of vaccines against respiratory pathogens previously difficult to vaccinate against (211).”
BackgroundAl-Abkal, J., Rebchuk, A. D., Lyndon, D., & Randhawa, N. (2021) · Cureus · doi:10.7759/cureus.20460 · Cited by 18
“In addition, incidence rates of these disorders peak during early and middle adulthood when fewer vaccines of any kind are being administered in comparison to young children and older adults [12].”
BackgroundInfluentialCOVID-19 vaccination: Why extend the interval between doses?
Quach, C., & Deeks, S. L. (2021) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2021-0323 · Cited by 16
Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2
Sharma, G., Song, L. F., & Merz, K. M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01283 · Cited by 19
Nam, S. Y., Jeon, S. W., Lee, H. S., Lim, H. J., Lee, D. W., & Yoo, S. S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12996 · Cited by 19
mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13974 · Cited by 16
“No new safety signals were reported than those already reported after 2 months of follow-up (Polack et al., 2020), indicating that this mRNA vaccine continued to be safe.”
BackgroundInfluentialOgrič, M., Žigon, P., Podovšovnik, E., Lakota, K., Sodin‐Šemrl, S., Rotar, Ž., & Čučnik, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876533 · Cited by 16
“The efficacy of two doses of the vaccine BNT162b2 (Comirnaty, Pfizer and BioNTech), a single-stranded mRNA carrying the spike (S) protein transcript, located in lipid nanoparticles, is 95% (4), while protection against reinfection in previously infected individuals is estimated at 89% (7).”
BackgroundFahrner, J., Lahmar, I., Goubet, A., Haddad, Y., Carrier, A., Mazzenga, M., Drubay, D., Silva, C. A. C., Lyon COVID Study Group, de Sousa, E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1441 · Cited by 22
“Vaccine-Induced S1-RBD Th1 Immunity Observed in Patients with Solid Cancer Is Reduced in Hematologic Malignancies During the course of this study, SARS-CoV-2 mRNA and DNA vaccines were approved by the FDA and the European Medicines Agency (EMA) based on reports that they prevent SARS-CoV-2 infection with an efficacy o…”
BackgroundJaydev, F., Kumar, V., Khatri, J., Shahani, S., & Beganovic, S. G. (2022) · Case Reports in Hematology · doi:10.1155/2022/2036460 · Cited by 16
“Some of the common side effects of these vaccines include local injection site inflammation, fever, chills, fatigue, myalgia, arthralgia, and headache [9], which are primarily self-resolving within a couple of days.”
BackgroundItalian association for the study of the liver position statement on SARS-CoV2 vaccination
Russo, F. P., Piano, S. S., Bruno, R., Burra, P., Puoti, M., Masarone, M., Montagnese, S., Ponziani, F. R., Petta, S., & Aghemo, A. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.03.013 · Cited by 18
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
Liontos, M., Terpos, E., Markellos, C., Zagouri, F., Briasoulis, Α., Katsiana, I., Skafida, E., Fiste, O., Kunadis, E., Andrikopoulou, Α., et al. (2021) · Vaccines · doi:10.3390/vaccines9101148 · Cited by 14
“However, patients with cancer were excluded from SARSCoV-2 vaccine registrational trials and data regarding the safety and efficacy of vaccination in this population are lacking [5,6].”
BackgroundMehrotra, M., Lim, E., Lamba, K., Kamali, A., Lai, K., Meza, E., Szeto, I., Robinson, P. V., Tsai, C., Gebhart, D., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac246 · Cited by 16
Kim, J. S., Sun, Y., Balte, P., Cushman, M., Boyle, R., Tracy, R. P., Styer, L. M., Bell, T. D., Anderson, M. R., Allen, N. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45468-9 · Cited by 24
Immune-mediated liver injury following COVID-19 vaccination
Schinas, G., Polyzou, E., Dimakopoulou, V., Tsoupra, S., Gogos, C. A., & Akinosoglou, K. (2023) · World Journal of Virology · doi:10.5501/wjv.v12.i2.100 · Cited by 18
Ledda, C., Costantino, C., Motta, G., Cunsolo, R., Stracquadanio, P., Liberti, G., Maltezou, H., & Rapisarda, V. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7010009 · Cited by 22
“Although breakthrough infections mean that the virus broke through a protective barrier provided by the vaccine, it prevents COVID-19 in more than 90% of beneficiaries [14,15].”
BackgroundWankhede, D., Grover, S., & Hofman, P. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.072 · Cited by 18
“[4] Polack FP, Thomas SJ, Kitchin N, et al.”
BackgroundTesting and vaccination to reduce the impact of COVID-19 in nursing homes: an agent-based approach
Gómez-Vázquez, J. P., García, Y. E., Schmidt, A. J., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07385-4 · Cited by 16
Ortiz‐Prado, E., Izquierdo‐Condoy, J. S., Fernández-Naranjo, R., Simbaña‐Rivera, K., Vásconez-González, J., Lincango-Naranjo, E. P., Cordovez, S., Coronel, B., Delgado-Moreira, K., & Jimbo-Sotomayor, R. (2022) · Vaccines · doi:10.3390/vaccines10071047 · Cited by 19
Amodio, E., Minutolo, G., Casuccio, A., Costantino, C., Graziano, G., Mazzucco, W., Pieri, A., Vitale, F. M., Zarcone, M., & Restivo, V. (2022) · Vaccines · doi:10.3390/vaccines10030345 · Cited by 17
“Each of them was sent every day for a week after the first and the second dose, according to the time period of ARs surveillance in the BNT162b2 trial [15].”
BackgroundMethodResultInfluentialRose, J., & McCullough, P. A. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101011 · Cited by 19
RetractedNovel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challengePreprint
Hou, F., Zhang, Y., Liu, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.19.517190 · Cited by 16
Raddad, L. J. A., Chemaitelly, H., Ayoub, H., Yassine, H., Benslimane, F., Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., Al-Kanaani, Z., et al. (2021) · medRxiv · doi:10.1101/2021.07.25.21261093 · Cited by 15
Feng, Y., Chen, J., Yao, T., Chang, Y., Li, X., Xing, R., Li, H., Xie, R., Zhang, X., Wei, Z., et al. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00924-2 · Cited by 22
Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study
Stivanello, E., Beghelli, C., Cardoni, F., Giansante, C., Marzaroli, P., Musti, M. A., Perlangeli, V., Todeschini, R., & Pandolfi, P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.039 · Cited by 14
Binder, J., Winkeljann, J., Steinegger, K. M., Trnovec, L., Orekhova, D., Zähringer, J., Hörner, A., Fell, V. H. K., Tinnefeld, P., Winkeljann, B., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00747 · Cited by 16
COVID-19 Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series
Brogna, B., Bignardi, E., Brogna, C., Capasso, C., Gagliardi, G., Martino, A., & Musto, L. A. (2021) · Medicina · doi:10.3390/medicina57090891 · Cited by 16
Dalvie, N. C., Rodriguez‐Aponte, S. A., Hartwell, B. L., Tostanoski, L. H., Biedermann, A. M., Crowell, L. E., Kaur, K., Kumru, O. S., Carter, L. P., Yu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.03.433558 · Cited by 18
Delivery of mRNA Using Biomimetic Vectors: Progress and Challenges
Yin, M., Sun, H., Li, Y., Zhang, J., Wang, J., Liang, Y., & Zhang, K. (2024) · Small · doi:10.1002/smll.202402715 · Cited by 19
Matryba, P., Gawalski, K., Ciesielska, I., Horvath, A., Bartoszewicz, Z., Sieńko, J., Ambroziak, U., Malesa-Tarasiuk, K., Staniszewska, A., Gołąb, J., et al. (2022) · Vaccines · doi:10.3390/vaccines10030443 · Cited by 16
“, older [33], dialyzed [34], immunocompromised [35] or patients with hematologic malignancies [36] and evident need for additional vaccine doses in otherwise healthy subjects [37], it is critical to search for the most optimal conditions for mounting the immune response against SARS-CoV-2 [38].”
BackgroundEmergency department–based COVID‐19 vaccination: Where do we stand?
Waxman, M., Moschella, P., Duber, H. C., Martin, D. R., Benzoni, T., Rothman, R. E., & Schechter‐Perkins, E. M. (2021) · Academic Emergency Medicine · doi:10.1111/acem.14261 · Cited by 16
Wan, E. Y. F., Chui, C. S. L., Mok, A. H. Y., Xu, W., Yan, V. K. C., Lai, F. T. T., Li, X., Wong, C. K. H., Chan, E. W., Lui, D. T. W., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01228-6 · Cited by 18
Multiple Evanescent White Dot Syndrome following COVID-19 mRNA Vaccination in Two Patients
Smith, E., Tran, T., Gillies, A., et al. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2032198 · Cited by 16
“The BNT162b2 vaccine is an mRNA vaccine that is one of the most common vaccines used to combat the COVID-19 pandemic after the phase 3 study demonstrated a two-dose vaccine efficacy rate of 95% against SARS-COV-2 in patients 16 years and older.(11) Currently, over 6.”
Moser, T., Otto, F., O'Sullivan, C., Hitzl, W., Pilz, G., Harrer, A., Trinka, E., & Wipfler, P. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103560 · Cited by 16
Rouger, J., Bertrand, Y., Boissel, N., Brethon, B., Ducassou, S., Gandemer, V., Domenech, C., Leblanc, T. M., Leverger, G., Michel, G., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.02.004 · Cited by 16
Chiampas, G., & Ibiebele, A. L. (2021) · Sports Medicine · doi:10.1007/s40279-021-01503-z · Cited by 17
Kahn, B., Apostolidis, S. A., Bhatt, V., Greenplate, A. R., Kallish, S., LaCava, A. F., Lucas, A., Meyer, N. J., Negoianu, D., Ogdie, A., et al. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000578 · Cited by 18
Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development
Francis, Z., Incerti, S., Zein, S. A., Lampe, N., Guzmán, C. A., & Durante, M. (2021) · Radiation Research · doi:10.1667/rade-20-00241.1 · Cited by 16
Comprehensive antibody profiling of mRNA vaccination in childrenPreprint
Bartsch, Y. C., Denis, K. S., Kapłonek, P., Kang, J., Lam, E. C., Burns, M. D., Farkas, E. J., Davis, J. P., Boribong, B. P., Edlow, A. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.07.463592 · Cited by 16
“mRNA vaccine platforms responded rapidly to SARS-CoV-2 threat, demonstrating robust levels 204 of efficacy in adults(26, 27).”
BackgroundHui, A., Li, J., Zhu, L., Tang, R., Ye, H., Lin, M., Ge, L., Wang, X., Peng, F., Wu, Z., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100586 · Cited by 19
Self-citationEsmaeilzadeh, A., Maleki, A. J., Moradi, A., Siahmansouri, A., Barhaghtalab, M. J. Y., Karami, P., & Elahi, R. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2116008 · Cited by 17
Singh, G., Abbad, A., Kleiner, G., Srivastava, K., Gleason, C., PARIS Study Group, Carreño, J. M., Simon, V. R., Krammer, F., Andre, D., et al. (2023) · mBio · doi:10.1128/mbio.02250-23 · Cited by 19
Jarisch, A., Wiercinska, E., Huenecke, S., Bremm, M., Cappel, C., Hauler, J., Rettinger, E., Soerensen, J., Hellstern, H., Klusmann, J., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.04.017 · Cited by 18
“6% clinical efficacy in the general population [5].”
Nelli, F., Fabbri, A., Onorato, A., Giannarelli, D., Silvestri, M. A., Berrios, J. R. G., Virtuoso, A., Marrucci, E., Signorelli, C., Chilelli, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.009 · Cited by 15
Flickinger, J. C., Staudt, R. E., Singh, J., Carlson, R. D., Barton, J. R., Baybutt, T. R., Rappaport, J. A., Zalewski, A., Pattison, A. M., Waldman, S. A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00483-z · Cited by 17
Shukla, P., Pandey, P., Prasad, B., Robinson, T., Purohit, R., D'Cruz, L. G., Tambuwala, M. M., Mutreja, A., Harkin, J., Singh, T., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab496 · Cited by 17
BEREZNE, A., Bougon, D., Blanc‐Jouvan, F., Gendron, N., Janssen, C., Müller, M., Bertil, S., Desvard, F., Présot, I., Terrier, B., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12572 · Cited by 16
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination
Walmsley, S. L., Nabipoor, M., Lovblom, L. E., Ravindran, R., Colwill, K., McGeer, A., Dayam, R. M., Manase, D., Gingras, A., & on behalf of the STOPCoV Team (2023) · Vaccines · doi:10.3390/vaccines12010036 · Cited by 15
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2
Markewitz, R. D. H., Juhl, D., Pauli, D., Görg, S., Junker, R., Rupp, J., Engel, S., Steinhagen, K., Herbst, V., Zapf, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.811020 · Cited by 14
“Among the first vaccines to be approved were the two mRNA-based vaccines BNT162b2 (Comirnaty; BioNTech/Pfizer, Germany/ USA) (1) and mRNA-1273 (Spikevax; Moderna, USA) (2) and the adenoviral vector vaccine ChAdOx1 nCoV-19 (Vaxzevria; Oxford-AstraZeneca, UK/Sweden) (3).”
BackgroundSølund, C. S., Underwood, A. P., Fernandez-Antunez, C., Bollerup, S., Mikkelsen, L. S., Villadsen, S. L., Fahnøe, U., Winckelmann, A. A., Feng, S., Vinten, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10010075 · Cited by 17
“The conditional approvals were based on interim analyses from phase 3 randomized double blinded placebo-controlled trials that showed a vaccine efficacy of 70% for Vaxzevria® [11] and 94 and 95% for Spikevax® [12] and Comirnaty® [13], respectively.”
MethodInfluentialTseng, Y., Liao, G., Lien, A., & Hsu, W. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.032 · Cited by 16
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Niesen, M. J. M., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Gordon, J. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac082 · Cited by 18
Choe, P. G., Hong, J., Park, J., Chang, E., Kang, C. K., Kim, N. J., Lee, C. H., Park, W. B., & Oh, M. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac099 · Cited by 17
“Recent reports on COVID-19 vaccines with strong efficacy provide hopes for pandemic control [15, 16], and many nations are pursuing the rollout of SARS-CoV-2 vaccination as an exit strategy from unprecedented social distancing [4].”
BackgroundChen, P., Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Gao, Y., Söderdahl, G., Österborg, A., Smith, C. I. E., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105385 · Cited by 17
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.026 · Cited by 18
Accelerating discoveries in cancer nanomedicine using AI
Guan, C., Mendes, B. B., Conniot, J., Dias, A. L., Hammad, L., Thambi, T., Langer, R., Rodrigues, T., Conde, J., & de la Fuente‐Núñez, C. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100279 · Cited by 20
van Nijnatten, T. J. A., Jochelson, M. S., & Lobbes, M. B. I. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110334 · Cited by 16
Impact of vaccination status on clinical outcomes of hospitalized COVID-19 patients
Jelodar, M. G., Mirzaei, S., Saghafi, F., Rafieian, S., Rezaei, S., Saatchi, A., Avare, Z. D., & Niri, M. D. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09139-w · Cited by 14
When does precision matter? Personalized medicine from the perspective of public health
Wilson, J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0013 · Cited by 17
Vaccination strategies for a seasonal epidemic: a simple SIR model
Nakamura, G. M., Grammaticos, B., & Badoual, M. (2021) · Open Communications in Nonlinear Mathematical Physics · doi:10.46298/ocnmp.7463 · Cited by 15
“In the case of COVID-19, which is the one we are interested in, the efficiency of existing vaccines has been established by several clinical studies [13, 14].”
Non-coding RNA and n6-methyladenosine modification play crucial roles in neuropathic pain
Zhang, K., Li, P., Jia, Y., Liu, M., & Jiang, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1002018 · Cited by 20
“Recently, Pfizer-BioNTech used the BNT162b2 COVID-19 vaccine successfully using mRNAbased lipid nanoparticles which showed 95% effectiveness in preventing COVID-19 (Polack et al., 2020).”
MethodSelf-citationVahidy, F., Pischel, L., Tano, M., Pan, A. P., Boom, M. L., Sostman, H. D., Nasir, K., & Omer, S. B. (2021) · medRxiv · doi:10.1101/2021.04.21.21255873 · Cited by 18
RetractedWang, C., Chen, C., Lu, C., Chen, W., Hui, R. C., Chiu, T., Chi, M., Lin, J.-C., Huang, Y., Chang, Y., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103054 · Cited by 17
Brlić, P. K., Pavletić, M., Lerga, M., Krstanović, F., Matešić, M. P., Miklić, K., Malić, S., Mikša, L., Pajcur, M., Peruč, D., et al. (2022) · Viruses · doi:10.3390/v14091966 · Cited by 20
“Following the first clinical studies of vaccine efficacy, it was hoped that the administration of vaccines would restrict virus spread [1,2].”
BackgroundInfluentialJubishi, D., Okamoto, K., Hamada, K., Ishii, T., Hashimoto, H., Shinohara, T., Yamashita, M., Wakimoto, Y., Otani, A., Hisasue, N., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2048559 · Cited by 16
“Local and systemic adverse reactions after vaccination with mRNA are frequent, and approximately two-thirds of the recipients reported local and/or systemic reactions after BNT162b2 vaccines in different studies.(3,19) While they are largely mild, they are considered a major cause of SARS-CoV-2 vaccine hesitancy.”
BackgroundEdwards, D. K., & Carfí, A. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102214 · Cited by 19
Kemerley, A., Gupta, A., Thirunavukkarasu, M., Maloney, M., Burgwardt, S., & Maulik, N. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030124 · Cited by 20
“The mRNA vaccines induce strong short-term immunity via an antibody response; however, these titers wane several months after the vaccine is administered and decline further around 8 months [101,105,106].”
BackgroundCastro‐Balado, A., Mondelo‐García, C., Barbosa‐Pereira, L., Varela-Rey, I., Novo‐Veleiro, I., Vázquez-Agra, N., López, J. R. A., Bandín‐Vilar, E., Sendón, R., Busto-Iglesias, M., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030342 · Cited by 16
Ringlander, J., Olausson, J., Nyström, K., Härnqvist, T., Jakobsson, H. E., & Lindh, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1957143 · Cited by 15
“During late 2020 and the beginning of 2021, vaccines have become available in many countries, and may halt the pandemic [1,2].”
BackgroundClinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines
Ritter, A., Helmchen, B., Gaspert, A., Bleisch, J., Fritschi, B., Buchkremer, F., Damm, S., Schmid, N., Schachtner, T., & Seeger, H. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab284 · Cited by 18
“While trials leading to initial emergency use authorization of these vaccines in the USA and Europe did not indicate major safety concerns, post-marketing observations—in particular in view of their large-scale use—will shed light on potential rare side effects and side effects in special populations [2, 3].”
BackgroundMagri, C., Marchina, E., Sansone, E., D’Adamo, P., Cappellani, S., Bonfanti, C., Terlenghi, L., Biasiotto, G., Zanella, I., Sala, E., et al. (2023) · HLA · doi:10.1111/tan.15157 · Cited by 21
Su, E., Fischer, S., Steingruber, R. D., Nigg, S., Güsewell, S., Albrich, W. C., Rothermundt, C. A., Silzle, T., & Kahlert, C. R. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100587 · Cited by 15
“Knowledge on the efficacy of the mRNA-based SARS-CoV2 vaccines in patients with actively treated solid malignant diseases, however, is still emerging as these patient groups had been excluded from the pivotal studies leading to approval of these vaccines.(4,5) Initial reports indicate that the humoral response after t…”
Davenport, B., Morrison, T. E., Kedl, R. M., & Klarquist, J. S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100195 · Cited by 16
Alshehri, S., & Sallam, M. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2275962 · Cited by 18
Stauft, C. B., Selvaraj, P., D’Agnillo, F., Meseda, C. A., Liu, S., Pedro, C. L., Sangare, K., Lien, C. Z., Weir, J. P., Starost, M. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39090-4 · Cited by 18
Akelew, Y., Henok, A., Ebrahim, E., Atnaf, A., & Hailemichael, W. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.573 · Cited by 19
Hatcher, S. M., Endres‐Dighe, S. M., Angulo, F. J., Srivastava, A. K., Nguyen, J. L., Khan, F. L., Martin, C., Swerdlow, D. L., McLaughlin, J. M., Ubaka-Blackmoore, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10030393 · Cited by 20
Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation
Atsavapranee, E., Haley, R. M., Billingsley, M. M., Chan, A., Ruan, B., Figueroa‐Espada, C. G., Gong, N., Mukalel, A. J., Bryan, P. N., & Mitchell, M. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.015 · Cited by 16
Sachak-Patwa, R., Byrne, H. M., Dyson, L., & Thompson, R. N. (2021) · Communications Medicine · doi:10.1038/s43856-021-00038-8 · Cited by 17
Mariani, M., Acquila, M., Tripodi, G., Spiazzi, R., & Castagnola, E. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.06.020 · Cited by 16
Tintle, S. J., & Chen, M. (2021) · eJHaem · doi:10.1002/jha2.265 · Cited by 16
“The development of mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been confirmed to be themost effective vaccines to drive potent adaptive immune responses against COVID19 virus infection.”
BackgroundInfluentialEick-Cost, A. A., Ying, S., & Wells, N. Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8071 · Cited by 18
Hanafy, B. I., Munson, M. J., Soundararajan, R., Pereira, S. G. T., Gallud, A., Sanaullah, S. M., Carlesso, G., & Mazza, M. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500383 · Cited by 32
Biomolecular interactions with nanoparticles: applications for coronavirus disease 2019
Farouq, M. A. H., Qaraghuli, M. M. A., Kubiak-Ossowska, K., Ferro, V. A., & Mulheran, P. A. (2021) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2021.101461 · Cited by 16
Hajbabaie, R., Harper, M. T., & Rahman, T. (2021) · Molecules · doi:10.3390/molecules26041134 · Cited by 18
Zhang, C., & Yang, M. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116083 · Cited by 20
“gov, NCT04368728) [80] and mRNA-1273 (ClinicalTrials.”
MethodInfluentialPaediatric research in the times of COVID-19
Fleming, P., Gale, C. P., Molloy, E. J., Faust, S. N., Costeloe, K., Juszczak, E., & Roehr, C. C. (2021) · Pediatric Research · doi:10.1038/s41390-021-01479-6 · Cited by 18
Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations
Cohen, S., Olshaker, H., Fischer, N., Vishnevskia‐Dai, V., Hagin, D., Rosenblatt, A., Zur, D., & Habot‐Wilner, Z. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2103831 · Cited by 15
Zelini, P., d'Angelo, P., Cereda, E., Klersy, C., Sabrina, P., Albertini, R., Grugnetti, G., Grugnetti, A., Marena, C., Cutti, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10081993 · Cited by 15
Leclerc, M., Redjoul, R., Bouter, A. L., Beckerich, F., Robin, C., Parinet, V., Pautas, C., Menouche, D., Bouledroua, S., Roy, L., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01250-2 · Cited by 16
“While hope has arisen a year ago from the promising results of messenger RNA (mRNA) vaccines studies [5, 6], showing high protection rates and a favorable safety profile, some concerns remain regarding the efficacy of vaccination in HSCT recipients, as humoral response might be altered in this setting because of conco…”
BackgroundRice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910136 · Cited by 16
“Impressive efforts of the scientific and pharmaceutical community have resulted in the design, testing and successful deployment of several COVID-19 vaccines that have shown high levels of efficacy [1-5].”
BackgroundCo‐Delivery of Multiple RNAs via Lipid Nanoparticles Enables Precise Gene Editing of CAR‐T Cells
Wang, M., Liao, Q., Bai, S., Liu, X., Peng, Y., Liu, P., Lu, H., Zhu, J., & Zeng, C. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501475 · Cited by 22
L’accès aux vaccins anti-COVID-19 dans un monde en crise : état des lieux et stratégies
OECD (2021) · Les réponses de l’OCDE face au coronavirus (Covid-19) · doi:10.1787/fe64d679-fr · Cited by 16
Beyond COVID-19: the promise of next-generation coronavirus vaccines
Mukesh, R. K., Yinda, C. K., Munster, V. J., & van Doremalen, N. (2024) · npj Viruses · doi:10.1038/s44298-024-00043-3 · Cited by 17
Digital Nanomedicine: A New Frontier for Drug Development
Ho, D. (2022) · ACS Nano · doi:10.1021/acsnano.2c01835 · Cited by 18
Evasion of Vaccine-Induced Humoral Immunity by Emerging Sub-Variants of SARS-CoV-2
Koyama, T., Miyakawa, K., Tokumasu, R., Jeremiah, S. S., Kudo, M., & Ryo, A. (2022) · Future Microbiology · doi:10.2217/fmb-2022-0025 · Cited by 16
“In particular, mRNA-1273 might provide better protection against the Beta+R346K strain, since mRNA-1273 seems more effective than BNT162b2 in general [31].”
BackgroundInfluentialMa, Y., Wang, Y., Dong, C., Gonzalez, G. X., Zhu, W., Kim, J., Wei, L., Kang, S., & Wang, B. (2022) · Small · doi:10.1002/smll.202200836 · Cited by 14
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.